According to the imaging and other examinations, those who evaluate the tumor can be basically completely resected should be operated first, and those who have difficulty in completely resecting the tumor should be biopsied only, and the diagnosis should be clarified by chemotherapy first and then surgery. Low-risk patients can be fully evaluated after 4 courses of chemotherapy, and discontinuation of chemotherapy can be considered if complete remission is achieved after 4 courses of chemotherapy, and the total number of courses of chemotherapy should not be more than 10. Those in the intermediate-risk group can be considered to stop the drug after 4-6 courses of chemotherapy after complete remission, with a maximum of 13 courses of chemotherapy, i.e., 42 weeks, and individualized adjustments of the regimen will be considered when more than 12 courses are given. Stem cell transplantation can be considered if the tumor foci are assessed to be in progression, the tumor is enlarged, or new foci are seen after 12 weeks of chemotherapy. For those in the high-risk group, if all chemotherapy is completed at 54 weeks, an individualized regimen is considered when the total course of treatment exceeds 12 courses, and stem cell transplantation is considered when the tumor is assessed to be in a state of disease progression. Rhabdomyosarcoma is a common childhood soft-tissue sarcoma that develops from abnormally growing early muscle cells and can occur in various parts of the body. It presents as a painless mass at the site of origin that may invade adjacent tissues and even develop distant metastases. Rhabdomyosarcoma is classified into embryonal rhabdomyosarcoma, vesicular rhabdomyosarcoma, pleomorphic or mesenchymal rhabdomyosarcoma according to histological types. Embryonal rhabdomyosarcoma accounts for 57% of all rhabdomyosarcoma cases and is the type of rhabdomyosarcoma with the best prognosis. The treatment of embryonal rhabdomyosarcoma is a combination of surgery, chemotherapy and radiotherapy. Chemotherapy is a very important component of treatment and is required for all risk groupings of embryonal rhabdomyosarcoma. Chemotherapy regimens used for the low-risk group include VAC, VA, intermediate-risk group chemotherapy regimens include VAC, VI, high-risk group chemotherapy regimens include VAC, VI, VDC, and IE, and central invasion group chemotherapy regimens include VAI, VAC, VDE, and VDI.